METHOD OF PREDICTING INTERFERON-RIVABIRIN-INDUCED NEUROPENIA IN PATIENTS WITH CHRONIC HEPATITIS C OBTAINING COMBINED ANTIVIRAL THERAPY Russian patent published in 2012 - IPC A61B10/00 G01N33/68 

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to infectious diseases. To predict interferon-ribaflavin-induced neuropenia in patients with chronic hepatitis C, obtaining combined antiviral therapy (CAT), phenomenon of induction of neutrophil apoptosis in vivo, determined by "skin window" technique, is used. Before administration of CFT to patients in impression-smears determination of induced neutrophil apoptosis is carried out. As apoptosis inductor, used is solution of 0.2 g of Rebetol and 1.7 mln IU Altevir, diluted in 1.0 l of isotonic solution. If in "skin window" high values of induced neutrophil apoptosis ≥40% is determined, high risk of neutropenia development in said category of patients in case of future carrying out to them CAT is predicted.

EFFECT: method makes it possible to predict interferon-ribaflavin-induced neuropenia in patients with chronic hepatitis C due to application as neutrophil apoptosis inducer of isotonic solution, consisting of rebetol and altevir, in vivo by "skin window" technique.

3 ex, 1 tbl